Nevro Corp
NYSE:NVRO
Intrinsic Value
Nevro Corp. engages in the provision of medical devices. [ Read More ]
The intrinsic value of one NVRO stock under the Base Case scenario is 45.7274 USD. Compared to the current market price of 12.0801 USD, Nevro Corp is Undervalued by 74%.
Valuation Backtest
Nevro Corp
Run backtest to discover the historical profit from buying and selling NVRO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Nevro Corp
Current Assets | 530.9m |
Cash & Short-Term Investments | 322.7m |
Receivables | 79.4m |
Other Current Assets | 128.8m |
Non-Current Assets | 104.8m |
PP&E | 33.5m |
Intangibles | 65.5m |
Other Non-Current Assets | 5.8m |
Current Liabilities | 83.4m |
Accounts Payable | 22.5m |
Accrued Liabilities | 49.5m |
Other Current Liabilities | 11.3m |
Non-Current Liabilities | 259.2m |
Long-Term Debt | 211.5m |
Other Non-Current Liabilities | 47.7m |
Earnings Waterfall
Nevro Corp
Revenue
|
425.2m
USD
|
Cost of Revenue
|
-135.1m
USD
|
Gross Profit
|
290.1m
USD
|
Operating Expenses
|
-389.4m
USD
|
Operating Income
|
-99.3m
USD
|
Other Expenses
|
7.1m
USD
|
Net Income
|
-92.2m
USD
|
Free Cash Flow Analysis
Nevro Corp
NVRO Profitability Score
Profitability Due Diligence
Nevro Corp's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Nevro Corp's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
NVRO Solvency Score
Solvency Due Diligence
Nevro Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Nevro Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NVRO Price Targets Summary
Nevro Corp
According to Wall Street analysts, the average 1-year price target for NVRO is 18.156 USD with a low forecast of 14.14 USD and a high forecast of 42 USD.
Ownership
NVRO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NVRO Price
Nevro Corp
Average Annual Return | 7.66% |
Standard Deviation of Annual Returns | 71% |
Max Drawdown | -93% |
Market Capitalization | 439.3m USD |
Shares Outstanding | 36 681 400 |
Percentage of Shares Shorted | 19.27% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nevro Corp. engages in the provision of medical devices. The company is headquartered in Redwood City, California and currently employs 945 full-time employees. The company went IPO on 2014-11-06. The firm has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.
Contact
IPO
Employees
Officers
The intrinsic value of one NVRO stock under the Base Case scenario is 45.7274 USD.
Compared to the current market price of 12.0801 USD, Nevro Corp is Undervalued by 74%.